scout

All News

BRISTOL, UK--A life-size model of a face with the look, feel, and color of real tissue allows medical students to recognize a wide variety of skin lesions--basal cell carcinomas, malignant melanomas, cysts, and warts--and practice a number of procedures, including lesion removal and planning of incisions.

Thiamine, which is usually given in excess to many cancer patients, should be carefully regulated in people undergoing cancer therapy, new research shows.

In a case with potentially national ramifications, Blue Cross & Blue Shield of Michigan has agreed to pay for high-dose chemotherapy with bone marrow or peripheral blood stem cell transplant support for cancer patients who were formerly denied coverage.

BETHESDA, Md--The Food and Drug Administration’s Biological Response Modifiers Advisory Committee voted to recommend approval of Stemgen (amcestim, r-metHuSCF), in combination with Neupogen (filgrastim, G-CSF), for use in mobilizing peripheral blood progenitor cells in cancer patients who undergo autologous stem-cell transplants in conjunction with high-dose chemotherapy. Both drugs are manufactured by Amgen, Inc.

WASHINGTON--A Federal appeals court has ruled that regulation of tobacco rests with Congress, not the FDA. In a 2-to-1 vote, a panel of the Fourth Circuit Court of Appeals, Richmond, Va, overturned a lower court ruling that had upheld FDA’s right to regulate tobacco.

The results of six studies examining novel cancer-fighting approaches designed to target cancer cells while potentially leaving healthy cells intact were discussed at a press conference held at the 34th Annual Meeting of the American Society of Clinical

SAN DIEGO--Researchers are becoming more optimistic about the possible benefits of recombinant vaccines in fighting carcinomas, Jeffrey Schlom, PhD, said at the American College of Physicians annual session.

BETHESDA, Md--Compliance problems cost millions of lives each year because patients fail to show up for screening, fail to come in for follow-up visits, don’t stick to their medications, or revert to unhealthy behavior, said Suzanne M. Miller, PhD, director of Psychosocial and Behavior Medicine, and senior member, Division of Population Science, Fox Chase Cancer Center.

WASHINGTON--A complaint filed with the Federal Election Commission (FEC) accuses five major tobacco companies of violating federal law by indicating they would pay for advertising to support the re-election bids of senators who voted against comprehensive tobacco legislation.

COLUMBUS, Ohio--The evaluation of a cancer patient’s complaint of pain should include an assessment of a variety of characteristics, including psychosocial and emotional factors, said Neil MacDonald, MD, director of the Cancer Ethics Programme, Center for Bioethics, Clinical Research Institute of Montreal.

SAN DIEGO--Researchers at the Fred Hutchinson Cancer Research Center, Seattle, have been monitoring the institution’s transplant patients for quality of life (QOL) for more than two decades, Keith Sullivan, MD, of the Department of Medical Oncology, said at the Sixth International Symposium on Recent Advances in Hematopoietic Stem Cell Transplantation, sponsored by the University of California, San Diego.

GENEVA--Highly active antiretroviral therapy (HAART), usually including a protease inhibitor, can suppress human immunodeficiency virus (HIV) so much that the immune system actually begins to heal, according to work presented at the 12th World Conference on AIDS. In patients who respond well to HAART, CD4+ and CD8+ cell counts move toward normal, and the risk of opportunistic infections decreases (see Oncology News International, August, 1998, pp 1 and 20).

COLUMBUS, Ohio--Recent clinical reports of nontraditional analgesics, like calcitonin, gabapentin (Neurontin), and tramadol (Ultram), suggest that these drugs may successfully control cancer pain in some patients, said Mary Beth Shirk, PharmD, clinical assistant professor, College of Pharmacy, Ohio State University. In some patients, the drugs have been shown to be effective against neuropathic pain.

Although almost all pituitary tumors are benign adenomas, a surprisingly large number of these tumors invade tissues outside of the pituitary gland. Such invasion, by itself, is not diagnostic of pituitary carcinomas, which are

Although almost all pituitary tumors are benign adenomas, a surprisingly large number of these tumors invade tissues outside of the pituitary gland. Such invasion, by itself, is not diagnostic of pituitary carcinomas, which are

LA JOLLA, California--Idun Pharmaceuticals, a biopharmaceutical company founded in 1994, is focusing its resources on the design and development of small molecule drugs targeting the biochemical pathways that control apoptosis, or programmed cell death.

BETHESDA, Md--As part of his sweeping reorganization and innovative effort at the National Cancer Institute, director Richard D. Klausner, MD, last November named 15 advocates to the Director’s Consumer Liaison Group (DCLG). Its recommendations will go directly to the NCI director, as it becomes a high-powered chartered advisory committee. Dr. Klausner envisioned a threefold purpose for this group of advocates. First, it will provide a forum for advocates to raise and discuss issues of concern regarding the development of NCI programs and research priorities. Second, it will help NCI develop criteria for selecting consumer advocates to serve on a number of NCI program and policy committees, including peer review panels. Third, it will serve as a strong link between NCI and cancer advocacy groups. Oncology News International’s Washington Bureau Chief Patrick Young discussed the DCLG’s role within NCI with Eleanor Nealon, director of NCI’s Office of Liaison Activities, which coordinates the group.

LOS ANGELES--Although a number of new angiogenesis inhibitors are under development, researchers reported at an ASCO poster session that an established anticancer agent may also have antiangiogenesis properties.

TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

ROCKVILLE, Md--The FDA has approved a new computer system, the M1000 ImageChecker, made by R2 Technology, Inc., Los Altos, California, to aid radiologists in reviewing mammograms. Studies show that use of the device improved the radiologists’ detection rate from approximately 80 out of 100 cancers to almost 88 out of 100.

WASHINGTON--Did some US senators pay the piper by helping defeat the McCain comprehensive tobacco control bill? That’s clearly the thesis of an analysis released by the Campaign for Tobacco-Free Kids. It found that senators who consistently voted against provisions to strengthen the bill, and ultimately to kill it, received far more in campaign contributions from the tobacco industry than those who strongly supported the bill.

GENEVA--Kaposi’s sarcoma (KS) and cervical dysplasia are common problems in HIV-infected patients. Research presented at the 12th World AIDS Conference shows that strong suppression of HIV replication with highly active antiretroviral therapy (HAART) also leads to recovery from these two neoplastic conditions.